摘要
唾液酸结合免疫球蛋白样凝集素-15(sialic acid-binding immunoglobulin-like lectin,Siglec-15)作为新发现的一种免疫检查点抑制剂(immune checkpoint inhibitors,ICIs),其广泛表达于多种肿瘤细胞,并与程序性死亡受体1(programmed cell death 1,PD-1)和程序性死亡受体-配体1(programmed cell death ligand 1,PD-L1)的表达互斥,可以作为一个新的ICIs治疗靶点,为PD-1/PD-L1治疗无响应的患者提供另一种治疗选择。本文拟从Siglec-15的特征通路、参与免疫调节机制以及在肿瘤相关的表达等方面的近期研究成果综述。分析研究Siglec-15抗体的临床应用结果,探讨Siglec-15在非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗中的应用意义以及治疗前景。
As a newly discovered ICI,Siglec-15 is widely expressed in various tumor cell types,and PD-1/PD-L1 expressions is mutually exclusive.Siglec-15 may be a new therapeutic target for PD-1/PD-L1 as a treatment option for patients who do not respond to therapy.This review discusses the recent research of the characteristic pathways of Siglec-15,its involvement in immune regulation mechanisms,and its tumor-related expression.Clinical application of an anti-Siglec-15 antibody was analyzed,and the therapeutic prospect of Siglec-15 for NSCLC treatment is discussed.
作者
李延康
贺钢枫
LI Yankang;HE Gangfeng(Baotou Central Hospital(the Baotou Affiliated Hospital of Inner Mongolia Medical University),Department of Cardiothoracic Surgery,Baotou 014000,China)
出处
《中国比较医学杂志》
CAS
北大核心
2023年第1期144-148,共5页
Chinese Journal of Comparative Medicine
基金
内蒙古医科大学百万工程(YKD2017KJBW(LW)048-544)。
